Sirtex acquires FDA-cleared Hourglass vascular plug for peripheral embolization
Sirtex acquires the FDA-cleared Hourglass vascular plug for peripheral embolization; the FDA approves Wilserdly for ESR1-mutated breast cancer and CMS proposes the CRUSH anti-fraud rule.
FDA approves Gazyva as first treatment for primary membranous nephropathy
The FDA approves Gazyva as the first treatment for primary membranous nephropathy; AstraZeneca's weekly self-injected Klygefa is approved for myasthenia gravis and CMS extends its hospice enrollment moratorium.
U.S. reported to lose measles elimination status after 26 years
The U.S. is reported to have lost its measles elimination status after 26 years; CMS lets states delay Medicaid work-requirement enforcement to mid-2027 and the FDA approves a new bladder cancer regimen.